Welcome to our dedicated page for Hcw Biologics SEC filings (Ticker: HCWB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Investors following HCW Biologics know the science is only half the story; deciphering how cytokine-based immunotherapies translate into cash runway, trial milestones and dilution risk is the other half—and it lives inside dense SEC paperwork. If you have ever searched “HCW Biologics SEC filings explained simply” after opening a 300-page 10-K, you’re not alone.
Stock Titan resolves that pain. Our AI scans every HCW Biologics annual report 10-K, quarterly earnings report 10-Q filing and 8-K material events the moment they hit EDGAR, then surfaces what matters: R&D spend trends, partnership revenue and upcoming phase-update dates. Prefer alerts? The platform pushes HCW Biologics insider trading Form 4 transactions in real time, delivering the “HCW Biologics Form 4 insider transactions real-time” data you need. Need governance details? We layer context onto each HCW Biologics proxy statement executive compensation table so you can see how option grants align with pipeline milestones—no accounting glossary required.
Whether you’re monitoring HCW Biologics executive stock transactions Form 4 before a data read-out or seeking a concise HCW Biologics earnings report filing analysis to model burn rate, our AI-powered summaries, side-by-side comparisons and smart search make understanding HCW Biologics SEC documents with AI straightforward. Stop toggling between PDFs; use one dashboard to track every filing type, from HCW Biologics annual report 10-K simplified to HCW Biologics 8-K material events explained in plain English.
HCW Biologics Inc. entered into an inducement agreement with a single institutional investor on November 19, 2025. The company reduced the exercise price of the investor’s existing November 2024 and May 2025 warrants from $7.45 per share to $2.66 per share, and the investor immediately exercised these warrants to purchase 1,510,205 shares of common stock. This generated approximately $4.0 million in gross proceeds for the company before fees and expenses.
In exchange for the exercise of the existing warrants, HCW Biologics issued new common stock purchase warrants to the investor for up to 3,020,410 shares at an exercise price of $2.41 per share, which are immediately exercisable and expire five and one-half years after their November 20, 2025 issuance. The company agreed to file a registration statement within 30 days to cover the resale of shares issuable upon exercise of the new warrants and engaged Maxim Group LLC as financial advisor, paying a 6.0% cash fee on the gross proceeds from the warrant exercise and up to $15,000 in reimbursable expenses.
HCW Biologics Inc. entered into an Amended and Restated License, Research and Co-Development Agreement with Beijing Trimmune Biotech covering the HCW11-006 molecule for in vivo applications. The deal restructures an earlier license so Trimmune pays a $7.0 million upfront fee, split into $3.5 million in cash at closing and $3.5 million in transferable equity in Trimmune valued from its current equity financing round. The agreement also gives Trimmune an option to license HCW9302 for in vivo use in China or Asia and sets a 90-day window from signing to close the transaction.
HCW Biologics keeps a payment-free, milestone-free, and royalty-free option to recapture rights to develop and commercialize HCW11-006 for in vivo applications in the United States, Canada, Central America, and South America after Phase 1 clinical trials. Trimmune will be financially responsible for research, development, manufacturing, clinical work, regulatory approvals, and commercialization in its territory. If the closing does not occur within 90 days of execution, all intellectual property and rights to HCW11-006 revert to HCW Biologics.
HCW Biologics Inc. reported that the first patient has been dosed in its company-sponsored, multi-center Phase 1 clinical trial of lead product candidate HCW9302 in patients with an autoimmune disorder. This marks an early clinical step for HCW9302 as the company moves from planning into active patient treatment under a formal trial setting. The update was shared through a press release dated November 18, 2025, which is furnished as an exhibit for informational purposes and not deemed filed for liability purposes under the securities laws.
HCW Biologics Inc. reported that a Nasdaq Hearings Panel granted an extension to regain compliance with continued listing requirements. The company must demonstrate compliance with the Nasdaq Equity Rule (Listing Rule 5550(b)(1)) by
The company is required to promptly notify the Panel of any significant events affecting compliance, timely file its Form 10-Q for the third quarter, and provide status updates on elements of its compliance plan. The Panel may review its decision within 45 calendar days after issuing the written decision and may request additional information before confirming compliance.
HCW Biologics reported a busy quarter with financing, licensing and construction developments that materially affect liquidity and operations. The company executed a one-for-forty reverse stock split effective April 11, 2025 and completed multiple financings: a registered direct/private placement that closed November 20, 2024, a follow-on public offering that closed May 15, 2025 raising gross proceeds of $5.0 million, bridge loans of $150,000 and $270,000 (the latter converted to equity), and other equity-related transactions valued at $15.2 million fair value of securities issued. HCW amended a license with WY Biotech that includes a $7.0 million upfront fee now expected by September 30, 2025, though revenue was not recognized because collectability was not probable. The company faces construction-related mechanics liens and litigation (BE&K, Fisk and related motions), reflected short-term debt classification due to lender acceleration rights, and recorded a $1.3 million fraud loss. A troubled debt restructuring converted $6.6 million of secured notes into equity, producing a non-cash gain recorded to additional paid-in capital.
HCW Biologics Inc. submitted a Form NT for its periodic report covering the period ended June 30, 2025, notifying the SEC that its Form 10-Q will be filed within the five-day grace period under Rule 12b-25. The notice identifies a prior quarter arbitration as the driver of materially higher legal costs in Q2 2024: $10.4 million of legal fees in Q2 2024 versus $142,452 in the same period of 2025, and states the arbitration was settled on July 13, 2024. The company lists Rebecca Byam, Chief Financial Officer, as the contact for the notification. The registrant indicates all other periodic reports required over the prior 12 months have been filed.
FAQ
What is the current stock price of Hcw Biologics (HCWB)?
What is the market cap of Hcw Biologics (HCWB)?
